Insmed's Brinsupri is the first DPP1 inhibitor approved by the FDA and the first treatment for bronchiectasis to reach the ...

Jefferies analysts said these detailed safety outcomes confirm the gene therapy's positive risk/benefit profile in ambulatory ...

Fred Roeder is a health economist and managing director of the Consumer Choice Center. He has worked in healthcare reform in ...

What if loyalty is holding you back? While it’s a sign of character, consistency and belief in a mission bigger than yourself ...

Novo Nordisk has plummeted back to Earth after a stunning rise driven by Ozempic and Wegovy. Can the storied Danish pharma ...

After a slow 2024, the biotech shell company Concentra Biosciences is back, offering to buy four biotechs in the past month ...

In May 2025, the White House announced a ‘Most Favored Nation’ approach for setting prescription drug prices. The order aims ...

Alastair Thomson, chief data officer at the HHS sub-agency, announced his resignation in opposition to Health Secretary ...

Sarepta’s troubles had nothing to do with Arrowhead’s assets, and yet both companies have seen their stock prices decline ...

For $1.3 billion in aggregate—including upfront and milestone payments—Bayer will get exclusive global access to Kumquat ...

The stop order came on Aug. 5, the same day Health Secretary Robert F. Kennedy Jr. terminated 22 mRNA vaccine projects under ...

The Annals of Internal Medicine ran a large-scale study in July, pointing to the lack of an association between childhood ...